Interleukin-33 (IL-33) is a member of the IL-1 cytokine superfamily that potently drives production of a variety of cytokines and contributes to the pathogenesis of inflammatory diseases. The IL-33 is a nuclear protein and is released from apoptotic or necrotic cells. Serum IL-33 levels are increased in various diseases, such as atopic dermatitis, chronic hepatitis C infection, and asthma. Here, we show that red blood cells (RBCs) are one of the major sources of plasma IL-33. The IL-33 levels are significantly increased in supernatants from lysed RBCs. Plasma IL-33 levels are increased in patients during hemolysis, and plasma IL-33 levels show a positive correlation with degree of hemolysis. The IL-33 protein and messenger RNA levels were detected in the late stages of differentiation in ex vivo primary human erythroid progenitor cell cultures, suggesting that IL-33 is expressed during maturation of RBCs. Furthermore, hemoglobin depleted red cell lysates induced IL-8 expression in human epithelial cells. This effect was attenuated in IL-33 decoy receptor expressing cells and was enhanced in IL-33 receptor expressing cells. These results suggest that erythroid progenitor cells produce IL-33 and circulating RBCs represent a major source of IL-33 that is released upon hemolysis.
LefrancaisE, RogaS, GautierV. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U SA. 2012; 109(5): 1673–1678.
2.
ZhaoJ, WeiJ, MialkiRK. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol. 2012; 13(7): 651–658.
3.
MoffattMF, GutIG, DemenaisF. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010; 363(13): 1211–1221.
4.
PrefontaineD, Lajoie-KadochS, FoleyS. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009; 183(8): 5094–5103.
LiD, GuabirabaR, BesnardAG. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol. 2014; 134(6): 1422–1432.
7.
PalmerG, Talabot-AyerD, LamacchiaC. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009; 60(3): 738–749.
8.
YuanFL, LiX, LuWG. IL-33: a promising therapeutic target for rheumatoid arthritis?Expert Opin Ther Targets. 2011; 15(5): 529–534.
9.
XuD, JiangHR, KewinP. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U SA. 2008; 105(31): 10913–10918.
10.
SchmitzJ, OwyangA, OldhamE. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5): 479–490.
11.
CarriereV, RousselL, OrtegaN. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U SA. 2007; 104(1): 282–287.
12.
ChackerianAA, OldhamER, MurphyEE. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007; 179(4): 2551–2555.
13.
YagamiA, OriharaK, MoritaH. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol. 2010; 185(10): 5743–5750.
14.
ZhaoJ, ChenQ, LiH. Lysophosphatidic acid increases soluble ST2 expression in mouse lung and human bronchial epithelial cells. Cell Signal. 2012; 24(1): 77–85.
15.
BabaY, MaedaK, YashiroT. GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: opposing roles for GATA2 and GATA1 in human IL1RL1/ST2 gene expression. J Biol Chem. 2012; 287(39): 32689–32696.
16.
NomuraK, KojimaT, FuchimotoJ. Regulation of interleukin-33 and thymic stromal lymphopoietin in human nasal fibroblasts by proinflammatory cytokines. Laryngoscope. 2012; 122(6): 1185–1192.
17.
MoussionC, OrtegaN, GirardJP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?PLoS One. 2008; 3(10): e3331.
18.
KuchlerAM, PollheimerJ, BaloghJ. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008; 173(4): 1229–1242.
19.
ZhangL, LuR, ZhaoG. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol. 2011; 43(9): 1383–1391.
20.
ShanJ, OshimaT, MutoT. Epithelial-derived nuclear IL-33 aggravates inflammation in the pathogenesis of reflux esophagitis. J Gastroenterol. 2015; 50(4): 414–423.
21.
CayrolC, GirardJP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014; 31C: 31–37.
22.
LuthiAU, CullenSP, McNeelaEA. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009; 31(1): 84–98.
23.
ZhaoWH, HuZQ. The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol. 2010; 7(4): 260–262.
24.
Tamagawa-MineokaR, OkuzawaY, MasudaK. Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol. 2014; 70(5): 882–888.
25.
KageyamaY, TorikaiE, TsujimuraK. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol. 2012; 22(1): 89–93.
26.
HongYS, MoonSJ, JooYB. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011; 26(9): 1132–1139.
27.
Raeiszadeh JahromiS, MaheshPA, JayarajBS. Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: a case-control study. J Asthma. 2014; 51(10): 1004–13.
28.
TerrasS, OpitzE, MoritzRK. Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Ann Rheum Dis. 2013; 72(1): 144–145.
29.
WallaceHW, CoburnRF. Relative thresholds for acute intravascular and extravascular mechanical hemolysis. J Thorac Cardiovasc Surg. 1974; 68(5): 792–796.
30.
LeeJS, GladwinMT. Bad blood: the risks of red cell storage. Nat Med. 2010; 16(4): 381–382.
31.
ThomasSL. Intravascular hemolysis: the sacrifice of few. Blood. 2014; 124(13): 2011–2012.
Roy-BurmanA, GladerBE. Resolution of severe Donath-Landsteiner autoimmune hemolytic anemia temporally associated with institution of plasmapheresis. Crit Care Med. 2002; 30(4): 931–934.
34.
KristianssonM, SoopM, SarasteL. Cytokines in stored red blood cell concentrates: promoters of systemic inflammation and simulators of acute transfusion reactions?Acta Anaesthesiol Scand. 1996; 40(4): 496–501.
35.
DarbonneWC, RiceGC, MohlerMA. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest. 1991; 88(4): 1362–1369.
36.
XiongZ, CavarettaJ, QuL. Red blood cell microparticles show altered inflammatory chemokine binding and release ligand upon interaction with platelets. Transfusion. 2011; 51(3): 610–621.
37.
PolychronakosC, RuggereMD, BenjaminA. The role of cell age in the difference in insulin binding between adult and cord erythrocytes. J Clin Endocrinol Metab. 1982; 55(2): 290–294.
38.
MorrisAH, JoyceJL, ReiterEO. Increased insulin-like growth factor I binding to red blood cells of normal prepubertal children. Pediatr Res. 1989; 25(4): 409–413.
EscobarGA, ChengAM, MooreEE. Stored packed red blood cell transfusion up-regulates inflammatory gene expression in circulating leukocytes. Ann Surg. 2007; 246(1): 129–134.
43.
NeoteK, DarbonneW, OgezJ. Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem. 1993; 268(17): 12247–12249.
44.
KappyMS. Insulin binding is a specific marker of fetal erythrocytes in ruminants. J Anim Sci. 1983; 56(5): 1153–1160.
45.
NouraieM, LeeJS, ZhangY. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013; 98(3): 464–472.
46.
LevescotA, FlamantS, BasbousS. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res. 2014; 74(10): 2669–2676.
47.
WatariK, MayaniH, LeeF. Production of interleukin 1beta by human hematopoietic progenitor cells. J Clin Invest. 1996; 97(7): 1666–16674.
